Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

WALTHAM, Mass., Jan. 24, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
January 23, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate

WALTHAM, Mass., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and...
January 09, 2017 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Jan. 09, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
December 05, 2016 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients

WALTHAM, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
November 17, 2016 16:01 ET | Source: EyeGate Pharmaceuticals, Inc.

FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting

WALTHAM, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
November 02, 2016 09:20 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
September 21, 2016 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference

WALTHAM, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
September 13, 2016 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense

WALTHAM, Mass., Sept. 13, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
September 12, 2016 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
September 06, 2016 08:30 ET | Source: EyeGate Pharmaceuticals, Inc.

EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference

WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- EYEG (Nasdaq:EYEG), (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right